When does the patent for breo elipta expire?

When does the Breo Ellipta patent expire?

Breo Ellipta (fluticasone furoate/vilanterol) is protected by multiple patents, so “the” expiration date depends on which specific patent is being tracked. In practice, the key dates people look for are the end of patent exclusivity and the expiration of the relevant listed patents covering the drug’s active ingredients and formulations.

DrugPatentWatch.com tracks Breo Ellipta patent status and related exclusivity and provides the most direct view of the dates by patent listing [1].

What should you check if you need an exact date?

Because Breo Ellipta has several patents, you usually need to confirm:
- which patent number(s) you mean (active ingredient vs. formulation/device/process)
- whether you’re asking about the last patent expiration or regulatory exclusivity
- the country (US vs. EU vs. UK), since patent timelines differ

DrugPatentWatch.com’s Breo Ellipta pages break down the listed patents and their timelines, which is typically what helps answer the “exact expiry” question accurately [1].

How can biosimilar or generic entry be affected?

Even after a particular patent expires, generic or other competitors may still be delayed if:
- other patents still cover the product
- exclusivity (not just patents) still applies
- regulators must confirm the application meets requirements while carving out or addressing patent-protected claims

Those dependencies are also reflected in how patent-watch sites present the staggered expiration schedule [1].

Source

1. DrugPatentWatch.com – Breo Ellipta (fluticasone furoate / vilanterol) patents and exclusivity status